This study aims to evaluate the therapeutic potential of Ivermectin, an FDA-approved antiparasitic drug commonly used for laboratory animals, for its anti-cancer efficacy. Specifically, the investigation will focus on its effects in a 4NQO-induced tongue tumor model of oral squamous cell carcinoma (OSCC) in C57BL/6 mice. The study will assess Ivermectin’s anti-tumor activity both as a monotherapy and in combination with Celecoxib, Erlotinib, and Methotrexate, clinically approved drugs routinely used in the metronomic chemotherapy of head and neck cancers. The goal is to determine the therapeutic benefits and underlying molecular mechanisms of Ivermectin-based interventions, potentially revealing novel combinatorial treatment strategies for OSCC
Lab members: Ms Sakshi Anchan, Ms Pooja Kohinkar, Mr Yadnyesh Girish Bhandari, Mr Sanket Bhadale
Co-Investigators: Dr Arvind Ingle, Dr Rahul Thorat, Dr Vikram Gota, Dr Amit Joshi